Autolus Therapeutics (NASDAQ:AUTL) Reaches New 12-Month Low - Here's What Happened

Shares of Autolus Therapeutics plc (NASDAQ:AUTL - Get Free Report) hit a new 52-week low on Tuesday . The company traded as low as $2.07 and last traded at $2.14, with a volume of 322885 shares changing hands. The stock had previously closed at $2.11.

Wall Street Analyst Weigh In

Several research firms recently commented on AUTL. Needham & Company LLC reiterated a "buy" rating and issued a $10.00 price objective on shares of Autolus Therapeutics in a research report on Monday, January 13th. Redburn Atlantic raised shares of Autolus Therapeutics from a "neutral" rating to a "buy" rating and set a $13.00 price target on the stock in a report on Friday, November 15th. Finally, The Goldman Sachs Group raised shares of Autolus Therapeutics from a "neutral" rating to a "buy" rating and raised their price objective for the stock from $7.00 to $7.60 in a research note on Monday, November 18th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $10.40.

Autolus Therapeutics Trading Down 3.3 %

The company's 50 day simple moving average is $2.42 and its 200-day simple moving average is $3.36. The company has a market capitalization of $540.16 million, a price-to-earnings ratio of -1.68 and a beta of 2.02.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.31) earnings per share for the quarter, missing analysts' consensus estimates of ($0.21) by ($0.10). During the same period in the prior year, the firm earned ($0.26) earnings per share. Sell-side analysts anticipate that Autolus Therapeutics plc will post -0.94 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Wellington Management Group LLP boosted its position in shares of Autolus Therapeutics by 35.4% in the third quarter. Wellington Management Group LLP now owns 24,220,226 shares of the company's stock worth $87,919,000 after acquiring an additional 6,330,392 shares during the last quarter. FMR LLC increased its holdings in shares of Autolus Therapeutics by 44.6% during the 3rd quarter. FMR LLC now owns 17,773,873 shares of the company's stock worth $64,519,000 after buying an additional 5,478,706 shares during the last quarter. Candriam S.C.A. purchased a new position in shares of Autolus Therapeutics in the 4th quarter worth $7,500,000. JPMorgan Chase & Co. boosted its holdings in Autolus Therapeutics by 145.3% in the third quarter. JPMorgan Chase & Co. now owns 1,284,708 shares of the company's stock valued at $4,663,000 after acquiring an additional 761,008 shares during the last quarter. Finally, Millennium Management LLC boosted its holdings in Autolus Therapeutics by 113.7% in the second quarter. Millennium Management LLC now owns 813,031 shares of the company's stock valued at $2,829,000 after acquiring an additional 432,503 shares during the last quarter. Institutional investors and hedge funds own 72.83% of the company's stock.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.